Targeted Therapy of Bronchiolitis Obliterans Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2015

Conditions
Bronchiolitis Obliterans
Interventions
DRUG

fluticasone propionate

Given inhaled PO

DRUG

montelukast sodium

Given PO

DRUG

azithromycin

Given PO

Trial Locations (11)

10065

Weill Cornell Medical College, New York

20892

National Cancer Institute Experimental Transplantation & Immunology Branch, Bethesda

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

37232

Vanderbilt University, Nashville

53226

Medical College of Wisconsin, Milwaukee

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

63110

Siteman Cancer Center at Washington University, St Louis

85054

Mayo Clinic - Scottsdale, Scottsdale

94305

Stanford University, Stanford

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Stephanie Lee

OTHER

NCT01307462 - Targeted Therapy of Bronchiolitis Obliterans Syndrome | Biotech Hunter | Biotech Hunter